13.57  -0.09 (-0.66%)		06-10 11:48
Open: 13.65 High: 14.27 Volume: 1,422,260		Pre. Close: 13.66 Low: 13.5201 Market Cap: 802(M)

Short term
Mid term
Targets	6-month :	16.66	1-year :	19.46
Resists	First :	14.27	Second :	16.66
Pivot price	11.3
Supports	First :	11.63	Second :	10.01
MAs	MA(5) :	12.25	MA(20) :	11.2
	MA(100) :	9.83	MA(250) :	9.7
MACD	MACD :	0.5	Signal :	0.3
%K %D	K(14,3) :	90.8	D(3) :	73.9
RSI	RSI(14): 71.2
52-week	High :	14.27	Low :	7.15

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ZVRA ] has closed above the upper band by 6.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 167.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	13.82 - 13.87	13.87 - 13.91
Low:	12.32 - 12.38	12.38 - 12.43
Close:	13.56 - 13.66	13.66 - 13.74

Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.

Wed, 10 Jun 2026
A Look At Zevra Therapeutics (ZVRA) Valuation As MIPLYFFA Patent Extension Targets 2041 Exclusivity - simplywall.st

Wed, 10 Jun 2026
Guggenheim raises Zevra Therapeutics price target on patent extension - Investing.com UK

Tue, 09 Jun 2026
BTIG raises Zevra Therapeutics price target to $27 on patent filing - Investing.com

Mon, 08 Jun 2026
Zevra Therapeutics (ZVRA) Files New Patent for Miplyffa - GuruFocus

Mon, 08 Jun 2026
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug - TradingView

Mon, 08 Jun 2026
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	59 (M)
Shares Float	55 (M)
Held by Insiders	1.3 (%)
Held by Institutions	70.7 (%)
Shares Short	4,440 (K)
Shares Short P.Month	4,780 (K)

EPS	2
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.72
Profit Margin	101.5 %
Operating Margin	24.3 %
Return on Assets (ttm)	2.7 %
Return on Equity (ttm)	100.6 %
Qtrly Rev. Growth	77.5 %
Gross Profit (p.s.)	1.78
Sales Per Share	2.06
EBITDA (p.s.)	0.21
Qtrly Earnings Growth	0 %
Operating Cash Flow	13 (M)
Levered Free Cash Flow	26 (M)

PE Ratio	6.83
PEG Ratio	10.6
Price to Book value	5.04
Price to Sales	6.63
Price to Cash Flow	63.56

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.